Synthelabo

Sanofi-synthelabo

Sanofi

Gareth Lewis

Maryvonne Chariot

Jean Montel

Frédéric Andre

Alain Cuine

G&eacute;rard Alaux

Howard Stevens

Francoise Arnold

Fr&eacute;d&eacute;ric Andre

Gérard Alaux

Michel Denni

Henri Da Cruz

Jérôme Mignonneau

Agnès Ribardiere

The invention concerns a pharmaceutical composition with gastric residence and controlled release, characterized in that it comprises two or three layers and contains (a) an active principle associated with a excipient modifying its release; (b) a system generating carbon dioxide in a swelling polymer hydrophilic matrix; (a) and (b) capable of being included in a common layer or in separate layers.

Pharmaceutical composition with gastric residence and controlled release

The present invention relates to controlled-release dosage forms of zolpidem or salts thereof adapted to release zolpidem over a predetermined time period, according to a biphasic profile of dissolution, where the first phase is an immediate release phase and the second phase is a prolonged release phase and particular embodiments thereof intended to avoid abuse.

Controlled-release dosage forms comprising zolpidem or a salt thereof

Slow-release pharmaceutical formulations containing mizolastine

A sustained-release pharmaceutical composition which comprises microparticles comprising an active principle, said microparticles being coated with a coating mixture comprising ethyl cellulose and an acrylic resin which is a polymerizate of acrylic and methacrylic ester, having a molecular weight of at least 100,000 and comprising units of formula: ##STR1## wherein: R.sub.1 is hydrogen or methyl,

Sustained release pharmaceutical composition of diltiazem

Growing community of inventors

Dourdan, France

Gareth Lewis